NAN 190

Drug Profile

NAN 190

Latest Information Update: 24 Aug 1998

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Nonindustrial source
  • Class Antihypertensives; Anxiolytics; Piperazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Hypertension; Major depressive disorder

Most Recent Events

  • 24 Aug 1998 No-Development-Reported for Depression in USA (Unknown route)
  • 24 Aug 1998 No-Development-Reported for Hypertension in Japan (Unknown route)
  • 24 Aug 1998 No-Development-Reported for Anxiety disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top